Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

Scott Drutman Incoming Chief Medical Officer of Enara Bio Boehringer Ingelheim exercises option to license additional Dark ...

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United ...

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...

"3T is tackling one of the toughest challenges in immuno-oncology: delivering potent, selective TCR therapies for solid tumors," said Dr. Knudsen. "The science is compelling, and the opportunity for ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...